| answer text |
<p>The Dame Barbara Windsor Dementia Mission was launched in August 2022 with £95
million of Government funding. There is now more than £120 million of committed funding
to the mission, which will be invested into three key pillars. The first pillar centres
on biomarkers and experimental medicine, and will receive £50 million of the funding
for the mission, with the intention of securing match funding from industry partners.
As part of this pillar, Innovate UK launched a Small Business Research Initiative
competition, with the aim of accelerating innovations in clinical biomarker tools
and technologies for dementia, where organisations could apply for a share of £6 million
of funding out of the allocated £50 million. These technologies will enable the discovery,
validation, and implementation of a suite of decision-enabling biomarkers to help
transform clinical trials and precision therapies. The competition closed on 4 September
2023, and the recipients awarded a portion of the £6 million will be announced soon.</p><p>
</p><p>The second pillar will focus on clinical trial infrastructure and innovation,
with two recently announced initiatives to support its delivery. The first of these
initiatives is the National Institute for Health and Care Research’s Dementia-Translational
Research Collaboration Trials Network, with almost £50 million of funding over five
years. This will expand the United Kingdom’s early phase clinical trial capabilities
for dementia, speeding up the development of new treatments. The second initiative
is the Clinical Trials Delivery Accelerator, focused on dementia, also named the Dementia
Accelerator. This was announced in the Autumn Statement 2023, in response to Lord
O’Shaughnessy’s independent review into commercial clinical trials in the UK, with
up to £20 million of additional funding.</p><p> </p><p>The third pillar will be focused
on end-to-end implementation, specifically on aligning translational research, clinical
practice, and regulatory frameworks to prepare health-systems for new dementia medicines.
The Medicines and Healthcare products Regulatory Agency, the National Institute for
Health and Care Excellence, NHS England, the Department, the devolved administrations,
and the Dame Barbara Windsor Dementia Mission are already working closely together
to plan for the implementation of new dementia medicines, should they gain approval
in the UK.</p>
|
|
